logo-loader

Tiziana's Milciclib drug meets primary endpoint in Phase 2a trial in Hepatocellular Carcinoma

Published: 10:54 14 May 2020 EDT

Tiziana Life Sciences (LON:TILS) CEO Kunwar Shailubhai speaks to Proactive London's Andrew Scott following the publication of two abstracts at the American Society of Clinical Oncology (ASCO) on the performance of its Milciclib drug in patients with advanced Hepatocellular Carcinoma. The first abstract reports Phase 2a clinical data with orally administered Milciclib in sorafenib-resistant hepatocellular carcinoma (HCC) patients, for which it met the primary endpoint. It says the oral treatment with Milciclib was well tolerated with manageable toxicities and no recorded drug-related deaths. The second abstract reports preliminary clinical data from an ongoing investigator-originated trial with a combination of orally administered Milciclib and Regorafenib in liver transplant patients with recurrent HCC.

Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced some fresh clinical results from its work in treating non-active secondary progressive...

on 10/16/2023